Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | HTR6 | P50406 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29759333 | 0.83 | ALDH1A1 (0.42) | TDP1MEN1HTTKMT2AGAA | |
| SCHEMBL4663299 | 0.83 | ALDH1A1 (0.42) | TDP1MEN1HTTKMT2AGAA | |
| SCHEMBL1868968 | 0.81 | GAA (0.40) | TDP1MEN1HTTKMT2AGAA | |
| SCHEMBL31206751 | 0.77 | CYP3A4 (0.37) | TDP1MEN1HTTKMT2AGAA | |
| SCHEMBL3208148 | 0.77 | CYP3A4 (0.37) | TDP1MEN1HTTKMT2AGAA | |
| SCHEMBL25402470 | 0.77 | KHK (0.36) | MEN1HTTKMT2A | |
| SCHEMBL22715880 | 0.77 | CYP1A2 (0.36) | TDP1MEN1KMT2AHTR6 | |
| SCHEMBL259983 | 0.75 | TDP1 (0.48) | TDP1MEN1HTTKMT2AGAA | |
| SCHEMBL1617849 | 0.75 | HTR6 (0.32) | GAAHTR6 | |
| SCHEMBL29462391 | 0.75 | TDP1 (0.48) | TDP1MEN1HTTKMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3740478-B1 | FUSED IMIDAZOLE DERIVATIVES AS IL-17 MODULATORS | UCB Biopharma SRL (BE) | 2023-11-01 | — | — | EP | disclosed |
| CN-111601799-B | Fused imidazole derivatives as Il-17 modulators | UCB生物制药有限责任公司 | 2023-06-09 | — | — | CN | disclosed |
| US-11472794-B2 | Fused imidazole derivatives as IL-17 modulators | UCB Biopharma SRL (BE) | 2022-10-18 | — | — | US | disclosed |
| CN-108467369-B | Biaryl amide compounds as kinase inhibitors | 诺华股份有限公司 | 2021-08-20 | — | — | CN | disclosed |
| US-20210053952-A1 | Fused Imidazole Derivatives as IL-17 Modulators | UCB Biopharma SRL (BE) | 2021-02-25 | — | — | US | disclosed |
| EP-3740478-A1 | FUSED IMIDAZOLE DERIVATIVES AS IL-17 MODULATORS | UCB Biopharma SRL (BE) | 2020-11-25 | — | — | EP | disclosed |
| CN-111601799-A | Fused imidazole derivatives as Il-17 modulators | UCB生物制药有限责任公司 | 2020-08-28 | — | — | CN | disclosed |
| US-10709712-B2 | Biaryl amide compounds as kinase inhibitors | NOVARTIS AG (CH) | 2020-07-14 | — | — | US | disclosed |
| US-20190175606-A1 | BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2019-06-13 | — | — | US | disclosed |
| US-10245267-B2 | Biaryl amide compounds as kinase inhibitors | NOVARTIS AG (CH) | 2019-04-02 | — | — | US | disclosed |
| US-20080318947-A1 | Inhibitors of Akt Activity | HEERDING DIRK A | 2008-12-25 | — | — | US | disclosed |
| EP-1874768-A2 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006113837-A2 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2006-10-26 | — | — | WO | disclosed |
| EP-0255217-B1 | FUSED IMIDAZOHETEROCYCLIC COMPOUNDS | A.H. ROBINS COMPANY, INCORPORATED (a Delaware corporation) (US) | 1992-01-22 | — | — | EP | disclosed |
| US-4948800-A | MUSCLE RELAXANTS; ANTICONVULSANTS; ANXIOLYTIC AGENTS; 3-HYDROXYALKYL-PYRIDO(4,5-B OR-C)IMIDAZOLE COMPOUNDS | A. H. ROBINS COMPANY, INCORPORATED (US) | 1990-08-14 | — | — | US | disclosed |
| US-4914109-A | ANTICONVULSANTS, ANTIANXIETY AGENTS | A. H. ROBINS COMPANY, INCORPORATED (US) | 1990-04-03 | — | — | US | disclosed |
| US-4873251-A | MUSCLE RELAXANTS, ANTICONVULSANTS, ANTIANXIETY AGENTS | A. H. ROBINS COMPANY, INCORPORATED (US) | 1989-10-10 | — | — | US | disclosed |
| US-4824951-A | MUSCLE RELAXANTS, ANTICONVULSANTS, ANXIOLYTIC AGENTS | A. H. ROBINS COMPANY, INCORPORATED (US) | 1989-04-25 | — | — | US | disclosed |
| US-4772600-A | MUSCLE RELAXANTS, ANTICONVULSANTS, ANXIOLYTIC | A. H. ROBINS COMPANY, INC. (US) | 1988-09-20 | — | — | US | disclosed |
| EP-0255217-A1 | Fused imidazoheterocyclic compounds | A.H. ROBINS COMPANY, INCORPORATED (a Delaware corporation) (US) | 1988-02-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11472794-B2 | Fused imidazole derivatives as IL-17 modulators | IL17A, IL2, IL23R | TDP1 3535/4885MEN1 2755/4885HTT 3006/4885 |
| US-10709712-B2 | Biaryl amide compounds as kinase inhibitors | BRAF, RAF1, NRAS | TDP1 1810/4885MEN1 2240/4885HTT 3841/4885 |
| US-20080318947-A1 | Inhibitors of Akt Activity | PI4KB, PIK3CA, AKT2 | TDP1 751/4885MEN1 3151/4885HTT 2591/4885 |
| US-20210053952-A1 | Fused Imidazole Derivatives as IL-17 Modulators | IL17A, IL2, IL23R | TDP1 3535/4885MEN1 2755/4885HTT 3006/4885 |
| US-20190175606-A1 | BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS | BRAF, RAF1, NRAS | TDP1 1810/4885MEN1 2240/4885HTT 3841/4885 |
| US-10245267-B2 | Biaryl amide compounds as kinase inhibitors | BRAF, RAF1, NRAS | TDP1 1810/4885MEN1 2240/4885HTT 3841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.